J. Nakielny

发表

The Fluoxetine and Suicide Controversy

D. Healy, J. Nakielny, 2012 .

Drisapersen treatment for Duchenne muscular dystrophy (DMD): results of a randomized, double-blind, placebo-controlled clinical trial of two doses for 24 weeks, followed by a 24-week post-treatment period

J. Kraus, C. McDonald, G. Campion, 2014 .

Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study

V. Ricotti, F. Muntoni, L. Servais, 2014, The Lancet Neurology.

Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: Results of a double-blind randomized clinical trial

K. Flanigan, L. Servais, T. Voit, 2013, Neuromuscular Disorders.

Seizures and antidepressants.

J. Nakielny, 1994, The British journal of psychiatry : the journal of mental science.

Effective and acceptable treatment for depression.

J. Nakielny, 1993, BMJ.

Drisapersen treatment for Duchenne muscular dystrophy: results of a 96-week follow-up of an open-label extension study following two placebo-controlled trials

Katie, M. Brin, C. Rowe, 2014 .

Fluoxetine and suicide

J. Nakielny, 1994, The Lancet.